246 related articles for article (PubMed ID: 19046489)
1. Screening for prostate cancer: an update.
Shariat SF; Scardino PT; Lilja H
Can J Urol; 2008 Dec; 15(6):4363-74. PubMed ID: 19046489
[TBL] [Abstract][Full Text] [Related]
2. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
[TBL] [Abstract][Full Text] [Related]
3. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
4. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
Vickers AJ; Ulmert D; Serio AM; Björk T; Scardino PT; Eastham JA; Berglund G; Lilja H
Int J Cancer; 2007 Nov; 121(10):2212-7. PubMed ID: 17657743
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
[TBL] [Abstract][Full Text] [Related]
8. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
Hugosson J; Aus G; Bergdahl S; Fernlund P; Frösing R; Lodding P; Pihl CG; Lilja H
BJU Int; 2003 Dec; 92 Suppl 2():39-43. PubMed ID: 14983953
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
11. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
[TBL] [Abstract][Full Text] [Related]
13. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran.
Safarinejad MR
Ann Oncol; 2006 Jul; 17(7):1166-71. PubMed ID: 16684791
[TBL] [Abstract][Full Text] [Related]
14. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
Rowe EW; Laniado ME; Walker MM; Patel A
BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
[TBL] [Abstract][Full Text] [Related]
16. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
[TBL] [Abstract][Full Text] [Related]
17. The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen.
Herrmann W; Stöckle M; Sand-Hill M; Hübner U; Herrmann M; Obeid R; Wullich B; Loch T; Geisel J
Clin Chem Lab Med; 2004; 42(9):1051-7. PubMed ID: 15497472
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
19. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
20. Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.
Rowe EW; Laniado ME; Walker MM; Anup P
BJU Int; 2006 May; 97(5):1039-42. PubMed ID: 16643488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
